279 The phase 3 HELIOS-B trial (NCT04153149), a multicenter, double-blind, randomized controlled trial, recently reported that vutrisiran reduced the primary endpoint, a composite of all-cause mortality and recurrent cardiovascular events, by 28% in the overall population and by 33% in the monotherapy subgroup
Effect of N-acetylcysteine on mitochondrial function following traumatic brain injury in rats
Despite its efficacy, some may be drawn to natural alternatives that align with a holistic approach to health
In RYBELSUS clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients receiving RYBELSUS (7 mg 0.6%, 14 mg 2%) than placebo (0.3%)
A: Generally, yesclinical trials show that higher doses of Tirzepatide are associated with greater overall weight loss, but always under careful medical supervision to manage side effects